IL318053A - Self-amplifying rna encoding an influenza virus antigen - Google Patents
Self-amplifying rna encoding an influenza virus antigenInfo
- Publication number
- IL318053A IL318053A IL318053A IL31805324A IL318053A IL 318053 A IL318053 A IL 318053A IL 318053 A IL318053 A IL 318053A IL 31805324 A IL31805324 A IL 31805324A IL 318053 A IL318053 A IL 318053A
- Authority
- IL
- Israel
- Prior art keywords
- self
- influenza virus
- rna encoding
- virus antigen
- amplifying rna
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36141—Use of virus, viral particle or viral elements as a vector
- C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/20—Vector systems having a special element relevant for transcription transcription of more than one cistron
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Plant Pathology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263359857P | 2022-07-10 | 2022-07-10 | |
| US202263431462P | 2022-12-09 | 2022-12-09 | |
| US202363484745P | 2023-02-13 | 2023-02-13 | |
| PCT/IB2023/057034 WO2024013625A1 (en) | 2022-07-10 | 2023-07-07 | Self-amplifying rna encoding an influenza virus antigen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL318053A true IL318053A (en) | 2025-02-01 |
Family
ID=87474458
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL318053A IL318053A (en) | 2022-07-10 | 2023-07-07 | Self-amplifying rna encoding an influenza virus antigen |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240009296A1 (en) |
| EP (1) | EP4551710A1 (en) |
| JP (1) | JP2025522946A (en) |
| KR (1) | KR20250034434A (en) |
| CN (1) | CN119866376A (en) |
| AU (1) | AU2023307581A1 (en) |
| CA (1) | CA3261474A1 (en) |
| IL (1) | IL318053A (en) |
| MX (1) | MX2025000397A (en) |
| TW (1) | TW202417018A (en) |
| WO (1) | WO2024013625A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4661903A1 (en) * | 2023-02-09 | 2025-12-17 | Pfizer Inc. | Nucleic acids and uses thereof |
| EP4665390A1 (en) | 2023-02-13 | 2025-12-24 | Pfizer Inc. | Immunogenic composition against influenza |
| AU2024342024A1 (en) | 2023-09-13 | 2026-03-26 | Pfizer Inc. | Immunogenic compositions against influenza |
| EP4788369A2 (en) | 2023-10-06 | 2026-08-12 | Pfizer Inc. | Immunogenic compositions |
| WO2025257691A1 (en) * | 2024-06-10 | 2025-12-18 | Seqirus Inc. | Potency assay |
| WO2026029847A1 (en) * | 2024-07-29 | 2026-02-05 | Arcturus Therapeutics, Inc. | Methods and compositions for pandemic influenza vaccine |
| WO2026126175A2 (en) | 2024-12-15 | 2026-06-18 | Pfizer Inc. | Immunogenic compositions against influenza |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2451475A2 (en) * | 2009-07-06 | 2012-05-16 | Novartis AG | Self replicating rna molecules and uses thereof |
| ES2993107T3 (en) * | 2016-10-17 | 2024-12-23 | Janssen Pharmaceuticals Inc | Recombinant virus replicon systems and uses thereof |
| AU2019321186B2 (en) * | 2018-08-17 | 2024-05-23 | Glaxosmithkline Biologicals Sa | Immunogenic compositions and uses thereof |
| US11241493B2 (en) * | 2020-02-04 | 2022-02-08 | Curevac Ag | Coronavirus vaccine |
| DE202021004130U1 (en) * | 2020-02-04 | 2022-10-26 | Curevac Ag | Coronavirus Vaccine |
| CN112546211A (en) * | 2020-10-23 | 2021-03-26 | 嘉晨西海(杭州)生物技术有限公司 | mRNA-based combined vaccine for coronavirus and influenza virus and preparation method thereof |
| AU2021392077A1 (en) * | 2020-12-02 | 2023-07-13 | Seqirus Inc. | Multicistronic rna vaccines and uses thereof |
-
2023
- 2023-07-06 US US18/347,698 patent/US20240009296A1/en active Pending
- 2023-07-07 WO PCT/IB2023/057034 patent/WO2024013625A1/en not_active Ceased
- 2023-07-07 AU AU2023307581A patent/AU2023307581A1/en active Pending
- 2023-07-07 CA CA3261474A patent/CA3261474A1/en active Pending
- 2023-07-07 KR KR1020257003647A patent/KR20250034434A/en not_active Withdrawn
- 2023-07-07 CN CN202380064603.5A patent/CN119866376A/en active Pending
- 2023-07-07 EP EP23745647.0A patent/EP4551710A1/en active Pending
- 2023-07-07 TW TW112125494A patent/TW202417018A/en unknown
- 2023-07-07 IL IL318053A patent/IL318053A/en unknown
- 2023-07-07 JP JP2025500762A patent/JP2025522946A/en not_active Withdrawn
-
2025
- 2025-01-09 MX MX2025000397A patent/MX2025000397A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025522946A (en) | 2025-07-17 |
| EP4551710A1 (en) | 2025-05-14 |
| WO2024013625A1 (en) | 2024-01-18 |
| CA3261474A1 (en) | 2024-01-18 |
| US20240009296A1 (en) | 2024-01-11 |
| TW202417018A (en) | 2024-05-01 |
| CN119866376A (en) | 2025-04-22 |
| KR20250034434A (en) | 2025-03-11 |
| MX2025000397A (en) | 2025-02-10 |
| AU2023307581A1 (en) | 2025-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3261474A1 (en) | Self-amplifying rna encoding an influenza virus antigen | |
| IL299169A (en) | Self-amplifying sars-cov-2 rna vaccine | |
| CY1124618T1 (en) | RECOMBINANT HVT VECTORS EXPRESSING Avian PATHOGEN ANTIGENS AND USES THEREOF | |
| GB2592769B (en) | CpG-Adjuvanted SARS-CoV-2 virus vaccine | |
| EP3938379A4 (en) | RNA VACCINES AGAINST HIV | |
| EP3568155A4 (en) | NUCLEOSIDE-MODIFIED RNA FOR INDUCING AN IMMUNE REACTION AGAINST ZIKA VIRUS | |
| EP4376883A4 (en) | RNA VACCINES | |
| PL2121011T3 (en) | Vaccines including antigen from four strains of influenza virus | |
| CA3267272A1 (en) | Influenza virus vaccines | |
| EP4413144A4 (en) | RNA VACCINE LIPIDNANO PARTICLES | |
| IL281299A (en) | A method for creating an RNA virus directed against a tumor and for creating mutants of the virus | |
| GB202219228D0 (en) | Novel influenza antigens | |
| EP4063383A4 (en) | Anti-varicella-zoster virus antibody | |
| ZA202209826B (en) | Inactivated sars-cov-2 virus vaccine | |
| EP4011453A4 (en) | ONCOLYTIC VACCINE VIRUS | |
| GB202314629D0 (en) | Influenza virus vaccines | |
| GB202306220D0 (en) | Influenza virus vaccines | |
| KR102211077B9 (en) | Pseudo-type rabies vaccine using virus-like particles | |
| AU2024260120A1 (en) | Influenza virus vaccines | |
| CA3288324A1 (en) | Influenza virus vaccines | |
| HK40122964A (en) | Influenza virus vaccines | |
| HK40076791A (en) | Hepatitis b virus vaccines | |
| AU2024301059A1 (en) | Rna vaccines | |
| AU2023902379A0 (en) | RNA vaccines | |
| GB202211076D0 (en) | Virus |